Format

Send to

Choose Destination
World J Gastroenterol. 2014 Feb 7;20(5):1298-304. doi: 10.3748/wjg.v20.i5.1298.

Antinociceptive effects of novel melatonin receptor agonists in mouse models of abdominal pain.

Author information

1
Chunqiu Chen, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.

Abstract

AIM:

To characterize the antinociceptive action of the novel melatonin receptor (MT) agonists, Neu-P11 and Neu-P12 in animal models of visceral pain.

METHODS:

Visceral pain was induced by intracolonic (ic) application of mustard oil or capsaicin solution or by intraperitoneal (ip) administration of acetic acid. Neu-P11, Neu-P12, or melatonin were given ip or orally and their effects on pain-induced behavioral responses were evaluated. To identify the receptors involved, the non-selective MT1/MT2 receptor antagonist luzindole, the MT2 receptor antagonist 4-P-PDOT, or the μ-opioid receptor antagonist naloxone were injected ip or intracerebroventricularly (icv) prior to the induction of pain.

RESULTS:

Orally and ip administered melatonin, Neu-P11, and Neu-P12 reduced pain responses in a dose-dependent manner. Neu-P12 was more effective and displayed longer duration of action compared to melatonin. The antinociceptive effects of Neu-P11 or Neu-P12 were antagonized by ip or icv. administered naloxone. Intracerebroventricularly, but not ip administration of luzindole or 4-P-PDOT blocked the antinociceptive actions of Neu-P11 or Neu-P12.

CONCLUSION:

Neu-P12 produced the most potent and long-lasting antinociceptive effect. Further development of Neu-P12 for future treatment of abdominal pain seems promising.

KEYWORDS:

Gastrointestinal tract; Melatonin; Neu-P11; Neu-P12; Opioid; Visceral pain

PMID:
24574803
PMCID:
PMC3921511
DOI:
10.3748/wjg.v20.i5.1298
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center